Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND Graves' disease is routinely treated with antithyroid drugs, radioiodine, or surgery, but whether the choice of initial therapy influences long-term outcomes is uncertain. We evaluated cardiovascular morbidity and mortality according to the method and effectiveness of primary therapy in Graves' disease. METHODS In this retrospective cohort study, we identified patients with hyperthyroidism, diagnosed between Jan 1, 1998, and Dec 31, 2013, from a thyroid-stimulating hormone (TSH)-receptor antibody (TRAb) test register in south Wales, UK, and imported their clinical data into the All-Wales Secure Anonymised Information Linkage (SAIL) Databank (Swansea University, Swansea, UK). Patients with Graves' disease, defined by positive TRAb tests, were selected for the study, and their clinical data were linked with outcomes in SAIL. We had no exclusion criteria. Patients were matched by age and sex to a control population (1:4) in the SAIL database. Patients were grouped by treatment within 1 year of diagnosis into the antithyroid drug group, radioiodine with resolved hyperthyroidism group (radioiodine group A), or radioiodine with unresolved hyperthyroidism group (radioiodine group B). We used landmark Kaplan-Meier and Cox regression models to analyse the association of treatment with the primary outcome of all-cause mortality and the secondary outcome of major adverse cardiovascular events (myocardial infarction, heart failure, ischaemic stroke, or death) with the landmark set at 1 year after diagnosis. We analysed the association between outcomes and concentration of TSH using Cox regression and outcomes and free thyroxine (FT4) concentration using restricted cubic-spline regression models. FINDINGS We extracted patient-level data on 4189 patients (3414 [81·5%] females and 775 [18·5%] males) with Graves' disease and 16 756 controls (13 656 [81·5%] females and 3100 [18·5%] males). In landmark analyses, 3587 patients were in the antithyroid drug group, 250 were in radioiodine group A, 182 were in radioiodine group B. Patients had increased all-cause mortality compared with controls (hazard ratio [HR] 1·22, 95% CI 1·05-1·42). Compared with patients in the antithyroid drug group, mortality was lower among those in radioiodine group A (HR 0·50, 95% CI 0·29-0·85), but not for those in radioiodine group B (HR 1·51, 95% CI 0·96-2·37). Persistently low TSH concentrations at 1 year after diagnosis were associated with increased mortality independent of treatment method (HR 1·55, 95% CI 1·08-2·24). Spline regressions showed a positive non-linear relationship between FT4 concentrations at 1 year and all-cause mortality. INTERPRETATION Regardless of the method of treatment, early and effective control of hyperthyroidism among patients with Graves' disease is associated with improved survival compared with less effective control. Rapid and sustained control of hyperthyroidism should be prioritised in the management of Graves' disease and early definitive treatment with radioiodine should be offered to patients who are unlikely to achieve remission with antithyroid drugs alone. FUNDING National Institute for Social Care and Health Research, Wales.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple imputation using chained equations: Issues and guidance for practice
White, I. R., Royston, P., & Wood, A. M. (2011) · Statistics in Medicine · doi:10.1002/sim.4067 · Cited by 9,792
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality
Sundararajan, V., Henderson, T., Perry, C., Muggivan, A., Quan, H., & Ghali, W. A. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.03.012 · Cited by 2,439
Global epidemiology of hyperthyroidism and hypothyroidism
Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552
Self-citationThe SAIL databank: linking multiple health and social care datasets
Lyons, R. A., Jones, K. H., John, G., Brooks, C. J., Verplancke, J.-P., Ford, D. V., Brown, G., & Leake, K. (2009) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-9-3 · Cited by 638
Cardiovascular involvement in patients with different causes of hyperthyroidism
Biondi, B., & Kahaly, G. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.105 · Cited by 230
A critical review and meta-analysis of the association between overt hyperthyroidism and mortality
Brandt, F., Green, A., Hegedüs, L., & Brix, T. H. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0299 · Cited by 170 · cited 2×
“hyperthyroidism control, from radioiodine therapy until control of hyperthyroidism, (3) RAI with hyperthyroidism control, following radioiodine control of hyperthyroidism; (4) Thyroidectomy, following thyroidectomy.”
BackgroundLillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L. (2018) · Thyroid · doi:10.1089/thy.2017.0517 · Cited by 150
Brandt, F., Thvilum, M., Almind, D., Christensen, K., Green, A., Hegedüs, L., & Brix, T. H. (2013) · Thyroid · doi:10.1089/thy.2012.0500 · Cited by 86
Boelaert, K., Maisonneuve, P., Torlinska, B., & Franklyn, J. A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3459 · Cited by 82 · cited 1×
“1016/S2213-8587(19)30059-2 Link to publication record in Explore Bristol Research PDF-document”
Background
Cited by
Lee, S. Y., & Pearce, E. N. (2023) · JAMA · doi:10.1001/jama.2023.19052 · Cited by 295
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis
Wiersinga, W. M., Poppe, K. G., & Effraimidis, G. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00005-0 · Cited by 254
Taylor, P. N., Lansdown, A., Witczak, J., Khan, R., Rees, A., Dayan, C. M., & Okosieme, O. (2023) · Thyroid Research · doi:10.1186/s13044-023-00149-5 · Cited by 72
“diac arrhythmias, and heart failure [78, 79], while hypo-”
BackgroundSelf-citationSohn, S. Y., Lee, E., Lee, M. K., & Lee, J. H. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.728 · Cited by 60
“After a full text review of 143 studies, 106 studies were further excluded, and 37 studies [5-11,13,15-17,20-44,46] were finally included for analysis.”
BackgroundInfluentialPostradioiodine Graves' management: The PRAGMA study
Perros, P., Basu, A., Boelaert, K., Dayan, C., Vaidya, B., Williams, G. R., Lazarus, J. H., Hickey, J., Drake, W. M., Crown, A., et al. (2022) · Clinical Endocrinology · doi:10.1111/cen.14719 · Cited by 16
Self-citation
Metadata
- Authors
- Okosieme, O. E., Taylor, P. N., Evans, C., Thayer, D., Chai, A., Khan, I., Draman, M. S., Tennant, B., Geen, J., Sayers, A., French, R., Lazarus, J. H., Premawardhana, L. D., & Dayan, C. M.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 7
- Issue
- 4
- Pages
- 278-287
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2917201966
- Cited by
- 131
- References
- 10
- FWCI
- 13.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30059-2
- The paper
- Okosieme, O. E., Taylor, P. N., Evans, C., Thayer, D., Chai, A., Khan, I., Draman, M. S., Tennant, B., Geen, J., Sayers, A., French, R., Lazarus, J. H., Premawardhana, L. D., & Dayan, C. M. (2019). Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30059-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.